DOI:
10.1055/s-00000140
Pädiatrie up2date
LinksClose Window
References
Kopp MV, Hamelmann E, Zielen S et al. DUAL study group.
Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
Clin Exp Allergy 2008;
39: 271-279
We do not assume any responsibility for the contents of the web pages of other providers.